Terrana Biosciences is a technology company.
Terrana Biosciences has raised $50.0M across 1 funding round.
Terrana Biosciences has raised $50.0M in total across 1 funding round.
Terrana Biosciences has raised $50.0M in total across 1 funding round.
Terrana Biosciences's investors include Alumni Ventures, Flagship Pioneering, Flagship Ventures.
Terrana Biosciences is a biotechnology company developing RNA-based solutions for agriculture, focusing on enhancing crop resilience, protecting yields from pests and diseases, and addressing climate challenges without altering plant genomes[1][2][3]. Backed by a $50 million initial investment from Flagship Pioneering, the company targets farmers growing specialty and row crops like tomatoes, corn, and soy, with a pipeline of over 15 products across three classes: Prevent (RNA vaccines priming immune responses), Protect (tools delivering peptides or molecules against infections), and Improve (traits like drought or heat tolerance applied via foliar sprays or seed treatments)[1][3][4]. Its platform fuses RNA technology with AI-driven computational biology to generate adaptive products deployable throughout a plant's lifecycle, offering faster, cheaper alternatives to traditional genetics or pesticides while minimizing environmental impact[2][6].
Founded in 2021 by Flagship Pioneering after four years of in-house platform development, Terrana emerged from stealth mode in July 2025 with the public unveiling of its RNA technology[1][2][3]. The idea builds on RNA innovations pioneered in human health, leveraging plants' natural self-replicating RNAs and input from experts like emeritus Penn State researcher Marilyn J. Roossinck to create a chassis from benign plant viruses for delivering protective RNA cargo[1][6]. Co-founder and CEO Ryan Rapp, an RNA and plant pathology expert, leads the experienced team; early proof-of-concept demonstrations in tomatoes, corn, and soy established a robust product pipeline, positioning Terrana for rapid scaling in crop protection[3][4].
Terrana rides the wave of RNA tech expansion from human medicine to agriculture, adapting viral RNA chassis—like mRNA vaccines—for crop "programming" against escalating threats from climate change, pests, and food security pressures[1][6]. Timing aligns with regulatory progress (e.g., EPA RNAi approvals) and demand for sustainable alternatives to chemical pesticides, as global yields face variability from warming and resistant pathogens[3][4][6]. Market forces favor it: AI-accelerated design scales pipelines rapidly, while Flagship's ag portfolio (e.g., Indigo Ag, Invaio) amplifies network effects; Terrana influences the ecosystem by pioneering "whole plant care," potentially slashing chemical use and enabling responsive farming in row/specialty crops[1][2][5].
Terrana's near-term focus on crop protection—led by tomato antivirals in 2-3 years—will test cost-effectiveness and market fit, with expansion into corn/soy resilience and partnerships via ag retail[4]. Rising climate extremes and biotech convergence (RNA + AI) will propel its platform toward broader traits like wet/cold tolerance and soil enhancement, evolving its role from stealth innovator to ecosystem shaper[3][4][6]. If scalable, Terrana could redefine ag biotech, delivering genome-free adaptability that keeps pace with nature's variability—transforming guesswork-based farming into precise, biology-driven protection[2][3].
Terrana Biosciences has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series B in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $50.0M Series B | Alumni Ventures, Flagship Pioneering, Flagship Ventures |